EUVIMEDEUVIMED entdecken
Crossref

Post‐marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System

Wei Zhuang iD, Jiabing Xu, Ye Wu, Jianhui Yang, Xiuxian Lin, Yufang Liao, Jun Wan, Lizhu Weng, Wanlong Lin

British Journal of Clinical Pharmacology · 2023-09 · 89 (9) · 2830-2842

DOI: 10.1111/bcp.15783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 25.05.2023. Verfasst von Wei Zhuang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China. Hauptthemen laut MEDLINE: COVID-19, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Natural Science Foundation of Xiamen City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Nirmatrelvir is an antiviral drug with a novel mechanism of action, targeting the 3‐CL protease, and is used in the treatment of COVID‐19. However, the potential side effects have not yet been fully studied. The aim of this study was to identify potential safety signals of nirmatrelvir by analysing post‐marketing safety data based on the largest publicly available worldwide pharmacovigilance database.

Methods

We analysed nirmatrelvir adverse events to identify and characterize relevant safety signals based on the FDA Adverse Event Reporting System database in 2022. The case/non‐case approach was used to estimate the reporting odds ratio (ROR) and information component (IC) with relevant confidence intervals (95% CI) for adverse events (AEs) that numbered 4 or more.

Results

A total of 26 846 cases were included. Disease recurrence (ROR [95% CI] = 413.2 [395.6–431.59]), dysgeusia (ROR [95% CI] = 110.84 [106.04–115.85]), anosmia (ROR [95% CI] = 15.21 [12.76–18.11]), ageusia (ROR [95% CI] = 9.80 [8.50–11.3]) and urticaria (ROR [95% CI] = 1.91 [1.69–2.17]) were the main safety signals. In addition, abdominal pain upper and skin toxicity were two specific safety signals of nirmatrelvir. In the pregnant population, there was a significant increased ROR for life‐threatening conditions (ROR [95% CI] = 8.00 [1.77–36.20]).

Conclusions

Our study identified that the main and specific safety signals of nirmatrelvir were disease recurrence, dysgeusia, abdominal pain upper and skin toxicity. Clinicians and pharmacists should be vigilant of these AEs, although differentiating between COVID‐19 symptoms and AEs can be challenging. Notably, a potential safety concern of nirmatrelvir should be a warning based on a small number of events in the pregnant population. However, the available data are insufficient, and further continued pharmacovigilance and surveillance is needed to fully understand this issue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Drug-Related Side Effects and Adverse ReactionsHumansUnited StatesDysgeusiaAdverse Drug Reaction Reporting SystemsPharmacovigilanceUnited States Food and Drug Administration

Stichwörter der Autor:innen

COVID-19FAERSnirmatrelvirpharmacovigilancepregnancysafety signalside effect

Autor:innen und Institutionen

  • Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China.
  • School of Pharmaceutical, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
  • Department of Ultrasound, The First Affiliated Hospital of Xiamen University, Xiamen, China.

ORCID-Profile: Wei Zhuang

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Natural Science Foundation of Xiamen City

Zitieren

APA

Zhuang, W., Xu, J., Wu, Y., Yang, J., Lin, X., Liao, Y., Wan, J., Weng, L., & Lin, W. (2023). Post‐marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. British Journal of Clinical Pharmacology, 89(9), 2830-2842. https://doi.org/10.1111/bcp.15783

Vancouver

Zhuang W, Xu J, Wu Y, Yang J, Lin X, Liao Y, et al. Post‐marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. British Journal of Clinical Pharmacology. 2023;89(9):2830-2842. doi:10.1111/bcp.15783

BibTeX
@article{Zhuang2023,
  author = {Zhuang, Wei and Xu, Jiabing and Wu, Ye and Yang, Jianhui and Lin, Xiuxian and Liao, Yufang and Wan, Jun and Weng, Lizhu and Lin, Wanlong},
  title = {Post‐marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  volume = {89},
  number = {9},
  pages = {2830--2842},
  doi = {10.1111/bcp.15783}
}
Kostenlos starten →